✦ LIBER ✦

Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcγRI × anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer

✍ Scribed by Repp, R; van Ojik, H H; Valerius, T; Groenewegen, G; Wieland, G; Oetzel, C; Stockmeyer, B; Becker, W; Eisenhut, M; Steininger, H

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical evaluation of the bispecific an

✍ H. H. van Ojik; R. Repp; Gerard Groenewegen; Thomas Valerius; Jan G. J. van de W 📂 Article 📅 1997 🏛 Springer-Verlag 🌐 English ⚖ 332 KB

676 - Bispeciffic antibody MDX210 (FcγRI

✍ Th. Valerius; B. Stockmeyer; R. Repp; Y. Deo; H. van Oijk; J.G. van de Winkel; J 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 246 KB

Pharmacokinetic–pharmacodynamic relation

✍ Lionel D Lewis; Bernard F Cole; Paul K Wallace; Jan L Fisher; Mary Waugh; Paul M 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 285 KB

Phase I trial of MDXH210 (FeγRI×HER-2/ne

📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 110 KB